Linked Life Data

15149796

Source:http://linkedlifedata.com/resource/pubmed/id/15149796

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17-18
pubmed:dateCreated
2004-5-19
pubmed:abstractText
To develop a CELO virus vector that can induce protection against infectious bursal disease, CELO viruses expressing the host-protective antigen VP2 of infectious bursal disease virus (IBDV) were constructed. In the engineered recombinants, the VP2 gene (the 441-first codons of the IBDA polyprotein) was placed under the control of the CMV promoter. Two positions in the CELO genome were chosen to insert the VP2 expression cassette. The recombinants were found apathogenic, when inoculated by different routes and even at high doses (up to 10(8) per animal). Chickens vaccinated oro-nasally with these different recombinants and challenged with very virulent IBDV were found to be poorly protected. In contrast, when inoculated with one or two (subcutaneous or intradermic) injections of CELOa-VP2, the chickens showed no clinical signs and no mortality after challenge. In the vaccinated chickens, the titers of neutralization antibody reached 7-9 values, showing that protection could be explained by the induction of a sufficient humoral response. After challenge, the weight ratio Bursa of Fabricius/body was about 2.5 per thousand, a value similar to that obtained with the commercial Bur706 vaccine. However, histological lesions in the Bursa of Fabricius were observed, showing that a complete protection was not totally achieved. Contact transmission was evidenced. Protection was also obtained when inoculation of CELOa-VP2 was carried out in ovo. Prime-boost strategies were also tested with the CELOa-VP2 vector used in association with the purified VP2 antigen, or DNA encoding VP2 or a CELO vector expressing chicken myeloid growth factor (cMGF). None of these regimens were shown to substantially increase the level of protection when compared to double CELOa-VP2 inoculations. These results indicate that CELO-based vectors are useful to safely induce a strong protective immunity against vvIBDV in chickens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
2
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2351-60
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:15149796-Animals, pubmed-meshheading:15149796-Antibodies, Viral, pubmed-meshheading:15149796-Birnaviridae Infections, pubmed-meshheading:15149796-Bursa of Fabricius, pubmed-meshheading:15149796-Chickens, pubmed-meshheading:15149796-Fowl adenovirus A, pubmed-meshheading:15149796-Gene Expression Regulation, Viral, pubmed-meshheading:15149796-Immunization, Secondary, pubmed-meshheading:15149796-Immunization Schedule, pubmed-meshheading:15149796-Infectious bursal disease virus, pubmed-meshheading:15149796-Neutralization Tests, pubmed-meshheading:15149796-Poultry Diseases, pubmed-meshheading:15149796-Promoter Regions, Genetic, pubmed-meshheading:15149796-Vaccination, pubmed-meshheading:15149796-Vaccines, Synthetic, pubmed-meshheading:15149796-Viral Structural Proteins, pubmed-meshheading:15149796-Viral Vaccines
pubmed:year
2004
pubmed:articleTitle
Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens.
pubmed:affiliation
Agence Française de Sécurité Sanitaire des Aliments, Molecular Biology Unit, Zoopôle Les Croix, B.P. 53, Ploufragan 22440, France.
pubmed:publicationType
Journal Article